I now have comprehensive material from multiple authoritative textbooks. Let me compile the complete notes.
Non-Sporing Anaerobes - Complete Notes
Sources: Medical Microbiology 9e (Murray), Jawetz Melnick & Adelberg's Medical Microbiology 28e, Sherris & Ryan's Medical Microbiology 8e
Overview and General Characteristics
Non-spore-forming anaerobes are a heterogeneous group of bacteria that form the predominant bacterial population on skin and mucosal surfaces of humans. They are primarily opportunistic pathogens responsible for endogenous infections, usually recovered in polymicrobial mixtures with aerobic bacteria.
Key features:
- Fail to grow in the presence of 10% O2; some killed by concentrations as low as 0.5%
- Lack cytochromes needed to use oxygen as terminal electron acceptor - generate energy solely by fermentation
- Most lack catalase and superoxide dismutase (enzymes that neutralize H2O2 and superoxide) - hence killed by O2
- Virulent pathogens (e.g., B. fragilis) do produce catalase/SOD as a virulence advantage
- Many have fastidious nutritional requirements and grow slowly on culture media
Classification of Non-Sporing Anaerobes
| Category | Key Organisms |
|---|
| Gram-positive cocci | Peptostreptococcus, Peptoniphilus, Anaerococcus, Finegoldia |
| Gram-negative cocci | Veillonella |
| Gram-positive rods | Actinomyces, Cutibacterium (formerly Propionibacterium acnes), Bifidobacterium, Eubacterium |
| Gram-negative rods | Bacteroides fragilis group, Prevotella, Porphyromonas, Fusobacterium |
A. Gram-Negative Rods
1. Bacteroides fragilis Group
Biology & Structure:
- Anaerobic, pleomorphic gram-negative rod (resembles mixed population on Gram stain)
- Growth is stimulated by bile (characteristic of the Bacteroides genus)
- Has typical gram-negative cell wall but LPS lacks endotoxin activity - lipid A lacks phosphate groups on glucosamine residues and has fewer fatty acids
- Surrounded by polysaccharide capsule - major virulence factor
- Normal stools contain 10¹¹ B. fragilis per gram (vs 10⁸/g for facultative anaerobes)
- Other B. fragilis group members: B. thetaiotaomicron, B. ovatus, B. vulgatus, B. distasonis
Epidemiology:
- Colonizes the gastrointestinal tract as a minor microbiome member
- Rare or absent from oropharynx or genital tract of healthy individuals
- Produces endogenous infections when gut mucosa is breached
Virulence Factors:
- Polysaccharide capsule - antiphagocytic; stimulates leukocyte migration and abscess formation
- Fimbriae - adhere to epithelial cells, fibrinogen, fibronectin, lactoferrin
- Short-chain fatty acids (succinic acid) - inhibit phagocytosis
- B. fragilis toxin (fragilysin) - heat-labile zinc metalloprotease; causes diarrheal disease by F-actin rearrangement in intestinal epithelium, stimulates chloride secretion, fluid loss, and IL-8 secretion
Diseases:
- Intraabdominal abscesses (most common - perforated appendix, diverticulitis, post-surgical)
- Pleuropulmonary infections
- Soft-tissue infections, skin infections
- Bacteremia
- Brain abscess (less common)
- Diarrheal disease (enterotoxigenic strains)
Diagnosis:
- Direct Gram stain from clinical specimens (faintly staining pleomorphic GNRs)
- Grows rapidly in anaerobic culture (unlike other anaerobic GNRs)
- Identification by biochemical tests, gene sequencing, or MALDI-TOF mass spectrometry
Treatment:
- Metronidazole - uniformly susceptible
- Carbapenems (imipenem, meropenem) - active against most strains
- Piperacillin-tazobactam, β-lactam + β-lactamase inhibitors
- Resistant to penicillin (β-lactamase producer)
- ~25% isolates resistant to clindamycin
- Resistant to most cephalosporins (exception: cefotaxime)
- Primary treatment: surgical drainage + antibiotics
2. Prevotella
Key features:
- Small gram-negative rods; previously classified as Bacteroides
- Normal inhabitants of the oral cavity, GI tract, and female genitourinary tract
- Pigmented species: Prevotella melaninogenica, P. intermedia - produce black colonies on blood agar (due to protoporphyrin)
- Other species: P. bivia, P. disiens (gynecologic infections)
Virulence:
- Fimbriae for adhesion
- Proteases that degrade immunoglobulins
- Short-chain fatty acids inhibit phagocytosis
Diseases:
- Oral/head and neck infections (P. melaninogenica, P. intermedia)
- Gynecologic infections - pelvic abscesses, endometritis (P. bivia, P. disiens)
- Aspiration pneumonia, lung abscess
- Brain abscess (polymicrobial)
- Associated with periodontal disease (P. intermedia)
Treatment: Metronidazole; β-lactam + β-lactamase inhibitor combinations
3. Porphyromonas
Key features:
- Very small gram-negative rods; previously classified as Bacteroides
- Colonize oral cavity and genitourinary tract
- P. gingivalis - key periodontal pathogen; produces gingipains (cysteine proteases)
- P. asaccharolytica - involved in head/neck and gynecologic infections
Virulence:
- Fimbriae of P. gingivalis induce proinflammatory cytokines (TNF-α, IL-1β)
- Proteases degrade immunoglobulins and complement
- Black-pigmented colonies
Diseases:
- Periodontal disease (P. gingivalis is major pathogen)
- Head and neck abscesses
- Gynecologic infections
4. Fusobacterium
Key features:
- Long, thin gram-negative rods with tapered ("fusiform") ends - spindly morphology
- ~13 species; most human infections caused by F. nucleatum and F. necrophorum
- Normal inhabitants of the oral cavity
F. nucleatum:
- Found in dental plaque; recurrent tonsillitis, brain abscess, bacteremia
- Female genital tract infections
F. necrophorum:
- Causes Lemierre syndrome (postanginal sepsis):
- Pharyngitis/tonsillitis → septic thrombophlebitis of internal jugular vein → metastatic septic emboli (lungs, joints, liver)
- Classically in young adults
- Unlike other anaerobic infections, Fusobacterium is often the sole organism isolated in Lemierre syndrome
- Also causes liver abscess, soft-tissue infections
Treatment: Metronidazole, penicillin (usually susceptible), β-lactam combinations
B. Gram-Negative Cocci
Veillonella
- Small gram-negative cocci that may resemble Neisseria on Gram stain
- Normal flora of the oral cavity, intestine
- Rarely pathogenic; may be isolated from mixed infections
- Inhabit oropharynx, GI tract; occasionally cause endocarditis, bacteremia, meningitis
C. Gram-Positive Cocci
Peptostreptococcus / Anaerobic Gram-Positive Cocci (AGPC)
(Includes genera: Peptostreptococcus, Peptoniphilus, Anaerococcus, Finegoldia magna)
Key features:
- Long chains of tiny cocci on Gram stain
- Reclassified from a single genus (Peptostreptococcus) into multiple genera based on gene sequencing
- Normal flora of oral cavity, GI tract, genitourinary tract, and skin
- Specific identification of different genera generally unnecessary clinically
Diseases (by site of origin):
- Oral/upper airway origin: sinusitis, pleuropulmonary infections
- Intestinal origin: intraabdominal infections
- Genitourinary origin: endometritis, pelvic abscess, salpingitis
- Skin origin: cellulitis, soft-tissue infections
- Hematogenous spread: osteomyelitis, solid organ abscesses, endocarditis
Treatment: Usually susceptible to penicillin, metronidazole, clindamycin
D. Gram-Positive Rods
1. Actinomyces
Key features:
- Thin, branching, filamentous gram-positive rods
- NOT a true anaerobe - microaerophilic (some are aerotolerant)
- Normal flora of oral cavity, GI tract, and vagina
- Infections are characteristically chronic (weeks to months to develop)
Virulence:
- No classic toxins; pathogenicity due to invasion of damaged mucosal barriers
Diseases:
- Cervicofacial actinomycosis (most common form - 50-60%) - "lumpy jaw"; associated with poor dental hygiene, dental trauma
- Thoracic actinomycosis - aspiration; mimics lung cancer
- Abdominal/pelvic actinomycosis - associated with IUD use (intrauterine device); follows bowel surgery or trauma
- Infection characterized by: chronic granulomatous lesions → suppurative abscesses → sinus tracts
- "Sulfur granules" (yellowish granules in pus) = tangled mass of gram-positive filamentous rods embedded in amorphous mineral deposits (hallmark of actinomycosis)
Diagnosis:
- Difficult - specimens must avoid oral contamination
- Sulfur granules should be crushed and examined microscopically - shows gram-positive branching rods
- Culture requires prolonged incubation (1 week or more) under anaerobic/microaerophilic conditions
- Many diagnoses not confirmed by culture; often clinical/histological
Treatment:
- Prolonged high-dose penicillin (weeks to months) - drug of choice
- Alternative: amoxicillin, tetracycline, clindamycin
- Responds slowly to antibiotics
2. Cutibacterium acnes (formerly Propionibacterium acnes)
Key features:
- Gram-positive rod; aerotolerant anaerobe
- Normal flora of skin (hair follicles, sebaceous glands)
- Produces propionic acid from glucose fermentation
Diseases:
- Acne vulgaris (role in pathogenesis via inflammatory mediators)
- Opportunistic infections in patients with prosthetic devices or intravascular lines (e.g., prosthetic joint infections, endocarditis, post-neurosurgical infections)
Treatment: Topical agents (benzoyl peroxide, antibiotics); systemic: tetracyclines, clindamycin
3. Bifidobacterium & Eubacterium
- Normal flora of the GI tract
- Rarely pathogenic; may be found in mixed infections
- Bifidobacterium found in infant intestines (first colonizers)
E. Laboratory Diagnosis of Non-Sporing Anaerobes
Specimen collection (critical):
- High-quality specimen: pus or fluid directly from infected site
- Must be transported in oxygen-free containers (anaerobic transport tubes) or syringe with all air expelled
- Cannot use swabs (contaminate with surface flora; expose to O2)
- Generous collection of pus = best transport medium
Gram stain:
- Direct smear showing pleomorphic gram-negative and/or gram-positive bacteria is highly suggestive of anaerobic infection
- Most useful test for clinical decision-making (culture results are delayed)
Culture:
- Anaerobic incubation atmosphere required (anaerobic jar with reducing agents)
- Enriched media (cysteine, thioglycollate, growth factors)
- Selective media with aminoglycosides (to which ALL anaerobes are resistant) to inhibit overgrowth by Enterobacteriaceae
- Incubation for 5-7 days (B. fragilis grows faster; others may take 3+ days)
- Identification: morphology, biochemical tests, MALDI-TOF mass spectrometry, gas chromatography of metabolic end-products
F. Treatment Principles
| Setting | Approach |
|---|
| Primary | Surgical drainage is essential - antibiotics alone may fail to penetrate |
| Oral anaerobes (above diaphragm) | Often susceptible to penicillin |
| Fecal anaerobes (below diaphragm) | Assume B. fragilis present - use metronidazole, carbapenem, or β-lactam + inhibitor |
| Empiric therapy | Based on expected organisms at anatomic site; culture-based ID is slow |
| Susceptibility testing | Not routinely available for anaerobes - empiric choices are standard |
Drug activity summary:
| Drug | Activity |
|---|
| Metronidazole | Uniformly active vs. all anaerobes including B. fragilis |
| Carbapenems (imipenem, meropenem) | Broad anaerobic coverage |
| Piperacillin-tazobactam | Active vs. most strains including B. fragilis |
| Penicillin | Active vs. oral anaerobes; B. fragilis is resistant (β-lactamase) |
| Clindamycin | Active vs. most; ~25% B. fragilis resistance |
| Aminoglycosides | INACTIVE vs. all anaerobes (used in selective media) |
G. Important Clinical Associations (High-Yield Summary)
| Organism | Key Association |
|---|
| B. fragilis | Intraabdominal abscess; polymicrobial; β-lactamase; LPS without endotoxin activity |
| Prevotella melaninogenica | Black-pigmented colonies; oral/head & neck infections |
| Porphyromonas gingivalis | Periodontal disease; fimbriae induce TNF-α, IL-1β |
| F. necrophorum | Lemierre syndrome (postanginal sepsis + IJV thrombophlebitis) |
| F. nucleatum | Dental plaque, brain abscess, colorectal cancer association |
| Actinomyces | Sulfur granules; chronic sinus tracts; IUD-associated pelvic infection |
| Peptostreptococcus | Mixed infections; pelvic, pleuropulmonary, intraabdominal |
| Veillonella | GN cocci mimicking Neisseria; oral/GI flora; rarely pathogenic |
| Cutibacterium acnes | Acne; prosthetic device infections |
Medical Microbiology 9e (Murray et al.), Chapter 31; Jawetz Melnick & Adelberg's Medical Microbiology 28e, Chapter 21; Sherris & Ryan's Medical Microbiology 8e, Chapter 29